Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT

Michael R. Bristow, Kavita Sharma, Susan F. Assmann, Stuart Linas, Bernard J. Gersh, Christine Grady, Madeline Murguia Rice, Steven Singh, Robin Boineau, Sonja M. Mckinlay, Barry H. Greenberg

Research output: Contribution to journalArticle

Abstract

Clinical trial Data and Safety Monitoring Boards (DSMBs) have a primary obligation of ensuring study participant safety, while maintaining trial integrity. The role of DSMBs is expanding, and ideally should include post-hoc reporting of deliberative processes related to clinically important safety issues or factors that could impact on future trial designs. We describe how the TOPCAT DSMB detected, investigated, and adjudicated an unexpectedly large renal adverse event signal midway through the trial, and offer general guidelines for dealing with similar unanticipated occurrences in future trials. The detection of a greater than expected incidence of deterioration in renal function, occurring in 6.1% of patients in the spironolactone arm compared with 3.9% in the placebo arm (P = 0.009), led to an in-depth DSMB review of associated study medication withdrawals and adverse events. The trial continued uninterrupted throughout the review, which reached the conclusions that spironolactone-associated renal dysfunction did not compromise overall patient safety or interfere with a perceived efficacy signal. Although no discrete mechanism for the spironolactone-associated renal adverse event signal was identified, likely possibilities are discussed. In clinical trials, DSMBs and co-ordinating centres should have the resources to detect, investigate, and adjudicate unexpected safety issues, with goals of ensuring patient safety and preserving the potential for detection of therapeutic effectiveness. In TOPCAT, spironolactone-associated renal dysfunction emerged as a potentially trial-threatening adverse event and, although clinically important, did not lead to compromise of patient safety, trial interruption, termination, or apparent loss of treatment effectiveness.

Original languageEnglish (US)
JournalEuropean Journal of Heart Failure
DOIs
StateAccepted/In press - 2016

Fingerprint

Clinical Trials Data Monitoring Committees
Spironolactone
Kidney
Patient Safety
Safety
Clinical Trials
Placebos
Guidelines
Incidence

Keywords

  • Clinical trials
  • Data and Safety Monitoring Boards
  • Heart failure with preserved ejection fraction
  • Mineralocorticoid receptor antagonists
  • Renal dysfunction
  • Spironolactone

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT. / Bristow, Michael R.; Sharma, Kavita; Assmann, Susan F.; Linas, Stuart; Gersh, Bernard J.; Grady, Christine; Rice, Madeline Murguia; Singh, Steven; Boineau, Robin; Mckinlay, Sonja M.; Greenberg, Barry H.

In: European Journal of Heart Failure, 2016.

Research output: Contribution to journalArticle

Bristow, MR, Sharma, K, Assmann, SF, Linas, S, Gersh, BJ, Grady, C, Rice, MM, Singh, S, Boineau, R, Mckinlay, SM & Greenberg, BH 2016, 'Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT', European Journal of Heart Failure. https://doi.org/10.1002/ejhf.686
Bristow, Michael R. ; Sharma, Kavita ; Assmann, Susan F. ; Linas, Stuart ; Gersh, Bernard J. ; Grady, Christine ; Rice, Madeline Murguia ; Singh, Steven ; Boineau, Robin ; Mckinlay, Sonja M. ; Greenberg, Barry H. / Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT. In: European Journal of Heart Failure. 2016.
@article{0d72e73ad9c14412923bae1d9ee9387a,
title = "Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT",
abstract = "Clinical trial Data and Safety Monitoring Boards (DSMBs) have a primary obligation of ensuring study participant safety, while maintaining trial integrity. The role of DSMBs is expanding, and ideally should include post-hoc reporting of deliberative processes related to clinically important safety issues or factors that could impact on future trial designs. We describe how the TOPCAT DSMB detected, investigated, and adjudicated an unexpectedly large renal adverse event signal midway through the trial, and offer general guidelines for dealing with similar unanticipated occurrences in future trials. The detection of a greater than expected incidence of deterioration in renal function, occurring in 6.1{\%} of patients in the spironolactone arm compared with 3.9{\%} in the placebo arm (P = 0.009), led to an in-depth DSMB review of associated study medication withdrawals and adverse events. The trial continued uninterrupted throughout the review, which reached the conclusions that spironolactone-associated renal dysfunction did not compromise overall patient safety or interfere with a perceived efficacy signal. Although no discrete mechanism for the spironolactone-associated renal adverse event signal was identified, likely possibilities are discussed. In clinical trials, DSMBs and co-ordinating centres should have the resources to detect, investigate, and adjudicate unexpected safety issues, with goals of ensuring patient safety and preserving the potential for detection of therapeutic effectiveness. In TOPCAT, spironolactone-associated renal dysfunction emerged as a potentially trial-threatening adverse event and, although clinically important, did not lead to compromise of patient safety, trial interruption, termination, or apparent loss of treatment effectiveness.",
keywords = "Clinical trials, Data and Safety Monitoring Boards, Heart failure with preserved ejection fraction, Mineralocorticoid receptor antagonists, Renal dysfunction, Spironolactone",
author = "Bristow, {Michael R.} and Kavita Sharma and Assmann, {Susan F.} and Stuart Linas and Gersh, {Bernard J.} and Christine Grady and Rice, {Madeline Murguia} and Steven Singh and Robin Boineau and Mckinlay, {Sonja M.} and Greenberg, {Barry H.}",
year = "2016",
doi = "10.1002/ejhf.686",
language = "English (US)",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",

}

TY - JOUR

T1 - Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT

AU - Bristow, Michael R.

AU - Sharma, Kavita

AU - Assmann, Susan F.

AU - Linas, Stuart

AU - Gersh, Bernard J.

AU - Grady, Christine

AU - Rice, Madeline Murguia

AU - Singh, Steven

AU - Boineau, Robin

AU - Mckinlay, Sonja M.

AU - Greenberg, Barry H.

PY - 2016

Y1 - 2016

N2 - Clinical trial Data and Safety Monitoring Boards (DSMBs) have a primary obligation of ensuring study participant safety, while maintaining trial integrity. The role of DSMBs is expanding, and ideally should include post-hoc reporting of deliberative processes related to clinically important safety issues or factors that could impact on future trial designs. We describe how the TOPCAT DSMB detected, investigated, and adjudicated an unexpectedly large renal adverse event signal midway through the trial, and offer general guidelines for dealing with similar unanticipated occurrences in future trials. The detection of a greater than expected incidence of deterioration in renal function, occurring in 6.1% of patients in the spironolactone arm compared with 3.9% in the placebo arm (P = 0.009), led to an in-depth DSMB review of associated study medication withdrawals and adverse events. The trial continued uninterrupted throughout the review, which reached the conclusions that spironolactone-associated renal dysfunction did not compromise overall patient safety or interfere with a perceived efficacy signal. Although no discrete mechanism for the spironolactone-associated renal adverse event signal was identified, likely possibilities are discussed. In clinical trials, DSMBs and co-ordinating centres should have the resources to detect, investigate, and adjudicate unexpected safety issues, with goals of ensuring patient safety and preserving the potential for detection of therapeutic effectiveness. In TOPCAT, spironolactone-associated renal dysfunction emerged as a potentially trial-threatening adverse event and, although clinically important, did not lead to compromise of patient safety, trial interruption, termination, or apparent loss of treatment effectiveness.

AB - Clinical trial Data and Safety Monitoring Boards (DSMBs) have a primary obligation of ensuring study participant safety, while maintaining trial integrity. The role of DSMBs is expanding, and ideally should include post-hoc reporting of deliberative processes related to clinically important safety issues or factors that could impact on future trial designs. We describe how the TOPCAT DSMB detected, investigated, and adjudicated an unexpectedly large renal adverse event signal midway through the trial, and offer general guidelines for dealing with similar unanticipated occurrences in future trials. The detection of a greater than expected incidence of deterioration in renal function, occurring in 6.1% of patients in the spironolactone arm compared with 3.9% in the placebo arm (P = 0.009), led to an in-depth DSMB review of associated study medication withdrawals and adverse events. The trial continued uninterrupted throughout the review, which reached the conclusions that spironolactone-associated renal dysfunction did not compromise overall patient safety or interfere with a perceived efficacy signal. Although no discrete mechanism for the spironolactone-associated renal adverse event signal was identified, likely possibilities are discussed. In clinical trials, DSMBs and co-ordinating centres should have the resources to detect, investigate, and adjudicate unexpected safety issues, with goals of ensuring patient safety and preserving the potential for detection of therapeutic effectiveness. In TOPCAT, spironolactone-associated renal dysfunction emerged as a potentially trial-threatening adverse event and, although clinically important, did not lead to compromise of patient safety, trial interruption, termination, or apparent loss of treatment effectiveness.

KW - Clinical trials

KW - Data and Safety Monitoring Boards

KW - Heart failure with preserved ejection fraction

KW - Mineralocorticoid receptor antagonists

KW - Renal dysfunction

KW - Spironolactone

UR - http://www.scopus.com/inward/record.url?scp=85005865093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85005865093&partnerID=8YFLogxK

U2 - 10.1002/ejhf.686

DO - 10.1002/ejhf.686

M3 - Article

C2 - 27873428

AN - SCOPUS:85005865093

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

ER -